Form 4 Novavax Inc For: 5 March
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Novavax Inc (NVAX)
Get information about the Novavax Stock. Find more details on NVAX stock to help you take informed decisions by going to one of the sections under this page - from Novavax Share Price historical data, charts and technical analysis to the balance sheet. Find Novavax quotes in the main stock markets such as NASDAQ and TradeGate, among others.
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.800
10.720
52 wk Range
5.010
11.970
NVAX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.80010.720
52 wk Range
5.01011.970
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NVAX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
13.778
Upside
+30.60%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Form 4 Novavax Inc For: 3 March
- Investing.com
- Form 4 Novavax Inc For: 5 March
- Investing.com
- Form 4 Novavax Inc For: 3 March
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Novavax Inc Earnings Call Summary for Q4/2025
- Novavax Q4 2025 EPS of $0.11 beat forecast of -$0.49; revenue hit $147M vs. expected $90.25M, exceeding projections by 62.88%
- Full-year 2025 revenue reached $1.1B, up 65% YoY, driven by Nuvaxovid sales and partnerships with Sanofi; R&D/SG&A expenses down 42%
- Cash position strengthened to $857M at year-end 2025, bolstered by $80M in non-dilutive capital received in early 2026
- Stock rose 1.58% to $9.681 in premarket trading following earnings beat, reflecting positive investor sentiment on operational execution
- Q1 2026 guidance projects EPS of -$0.33 with $60.4M revenue; company focusing on pipeline advancement and Matrix-M adjuvant expansion
Last Updated: 2026-02-26, 11:12 a/m
Read Full TranscriptCompare NVAX to Peers and Sector
Metrics to compare | NVAX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNVAXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 3.8x | −2.8x | −0.5x | |
PEG Ratio | 0.01 | −0.21 | 0.00 | |
Price/Book | −13.1x | 2.5x | 2.6x | |
Price / LTM Sales | 1.5x | 7.3x | 3.2x | |
Upside (Analyst Target) | 60.3% | 38.4% | 51.2% | |
Fair Value Upside | Unlock | 16.1% | 7.3% | Unlock |
Analyst Ratings
5 Buy
1 Hold
3 Sell
Ratings:
9 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 13.778
(+30.60% Upside)
Earnings
Latest Release
Feb 26, 2026
EPS / Forecast
0.11 / -0.49
Revenue / Forecast
147.00M / 90.25M
People Also Watch
FAQ
What Is the Novavax (NVAX) Stock Price Today?
The Novavax stock price today is 10.550 USD.
What Stock Exchange Does Novavax Trade On?
Novavax is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Novavax?
The stock symbol for Novavax is "NVAX."
What Is the Novavax Market Cap?
As of today, Novavax market cap is 1.710B USD.
What Is Novavax's Earnings Per Share (TTM)?
The Novavax EPS (TTM) is 2.575.
When Is the Next Novavax Earnings Date?
Novavax will release its next earnings report on May 13, 2026.
From a Technical Analysis Perspective, Is NVAX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Novavax Stock Split?
Novavax has split 1 times.
How Many Employees Does Novavax Have?
Novavax has 749 employees.
What is the current trading status of Novavax (NVAX)?
As of Mar 09, 2026, Novavax (NVAX) is trading at a price of 10.550 USD, with a previous close of 9.980 USD. The stock has fluctuated within a day range of 9.800 USD to 10.720 USD, while its 52-week range spans from 5.010 USD to 11.970 USD.
What Is Novavax (NVAX) Price Target According to Analysts?
The average 12-month price target for Novavax is 13.778 USD, with a high estimate of 25 USD and a low estimate of 7 USD. 5 analysts recommend buying the stock, while 3 suggest selling, leading to an overall rating of Buy. The stock has an +30.60% Upside potential.
What Is the NVAX Premarket Price?
NVAX's last pre-market stock price is 9.900 USD. The pre-market share volume is 50,120.000, and the stock has decreased by -0.080, or -0.800%.
What Is the NVAX After Hours Price?
NVAX's last after hours stock price is 10.520 USD, the stock has decreased by -0.030, or -0.280%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.